NCT01499602

Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women

LNG-IUS or Norethisterone Acetate for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Mansoura University · Academic / Other
• Sex: Female
• Age: 40 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy of the Levonorgestrel releasing Intrauterine System (Mirena) and Norethisterone Acetate for treatment of non-atypical endometrial hyperplasia in perimenopausal women.

Conditions

• Endometrial Hyperplasia

Interventions

Type	Name	Description
DRUG	LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland	Initial release rate of 20µg Levonorgestrel per day for one year follow up.
DRUG	Norethisterone Acetate tablets	Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months

Timeline

• Start date: 2009-05-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2011-12-26
• Last updated: 2011-12-26

Locations

1 site across 1 country: Egypt